Efficacy of antidepressants in the treatment of severe depression: The place of mirtazapine

Journal of Clinical Psychopharmacology

Volumn 17, Issue 2 SUPPL. 1, 1997, Pages

  Kasper, Siegfried ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; FLUOXETINE; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

CONFERENCE PAPER; DEPRESSION; DRUG EFFICACY; HUMAN; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; CLINICAL TRIALS; DEPRESSIVE DISORDER; HUMANS; MIANSERIN;

EID: 0030949402     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (52)

1. Danish University Antidepressant Group (DUAG). Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology 1986;90:131-8.
2. Danish University Antidepressant Group (DUAG). Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1990;18:289-99.
3. Danish University Antidepressant Group (DUAG). Moclobemide: a reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1993;28:105-16.
4. Anderson IM, Tomenson BM. The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol 1994;8: 238-49.
5. Nelson JC, Mazure CM, Bowers MJ Jr, Jatlow PI. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 1991; 48:303-7.
6. Preskorn SH. Should rational drug development in psychiatry target more than one mechanism of action in a single molecule? Int Rev Psychiatry 1995;7:17-28.
7. World Health Organization. The ICD-10 classification of mental and behavioural disorders, clinical descriptors and diagnostic guideline. Geneva; World Health Organization, 1992.
8. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
9. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9.
10. Nelson JC, Docherty JP, Henschen GM, Kasper S, Narenhap AA, Ward NG. Algorithms for the treatment of subtypes of unipolar major depression. Psychopharmacol Bull 1995;31:475-82.
11. Zimmerman M, Coryell WH, Pfohl B. Melancholic subtyping: a qualitative or quantitative distinction? Am J Psychiatry 1986; 143:98-100.
12. Parker G, Hadzi-Pavlovic D, Hickie I, Boyce P, Mitchell P, Wilhelm K, Brodaty H. Distinguishing psychotic and non-psychotic melancholia. J Affect Disord 1991;22:135-48.
13. Lipsitz J, Williams JBW. Assessment of severe depressive disorders. In: Grunhaus L, Greden JF, eds. Severe depressive disorders. Progress in psychiatry series, vol. 44. Washington, DC: American Psychiatric Press, 1994:1-22.
14. Hecht H, von Zerssen D, Wittchen HU. Anxiety and depression in a community sample: the influence of comorbidity on social functioning. J Affect Disord 1990;18:137-44.
15. Mirin SM, Weiss RD. Affective illness in substance abusers. Psychiatr Clin North Am 1986;9:503-14.
16. Coryell WH, Endicott J, Andreasen NC, Keller MB, Clayton PJ, Hirschfeld RM, Scheftner WA, Winokur G. Depression and panic attacks: the significance of overlap as reflected in follow-up and family study data. Am J Psychiatry 1988;145:293-300.
17. Maddux JF, Desmond DP, Costello R. Depression in opioid users varies with substance abuse status. Am J Drug Alcohol Abuse 1987;13:375-85.
18. Van Valkenburg C, Akiskal HS, Puzantian V, Rosenthal T. Anxious depressions: clinical, family history, and naturalistic outcomecomparisons with panic and major depressive disorders. J Affect Disord 1984;6:67-82.
19. Endicott J, Cohen J, Nee J, Fleiss J, Sarantakos S. Hamilton Depression Rating Scale: extracted from regular and charge versions of the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 1981;38:98-103.
20. Feinberg M, Carroll B, Smouse P, Rawson SG. The Caroll Rating Scale for Depression, III: comparison with other rating instruments. Br J Psychiatry 1981; 138:205-9.
21. Lader M. Fluoxetine efficacy vs comparative drugs: an overview. Br J Psychiatry 1988;153[suppl 3]:51-8.
22. Angst J, Bech P, Boyer P, Bruinvels J, Engel R, Helmchen H, Hippius H, Lingjaerde O, Racagni G, Saletu B, Sedvall G, Silverstone JT, Stefanis CN, Stoll K, Woggon B. Consensus conference on the methodology of clinical trials of antidepressants, Zurich, March 1988: report of the consensus committee. Pharmacopsychiatry 1989;22:3-7.
23. Anton RF Jr, Burch EA Jr. Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression. Am J Psychiatry 1990;147:1203-8.
24. Arminen S-L, Ikonen U, Pulkkinen P, Leinonen E, Mahlanan A, Koponen H, Kourula K, Ryyppö J, Korpela V, Lehtonen ML, Vartiainen H, Lehtinen V, Tamminen T, Manniche PM. A 12-week double-blind multi-centre study of paroxetine and imipramine in hospitalized depressed patients. Acta Psychiatr Scand 1994; 89:382-9.
25. Roose SP, Glassman AH, Attia E, Woodring S. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia Am J Psychiatry 1994; 151:1735-9.
26. Spiker DG, Weiss JC, Dealy RS, Griffin SJ, Hanin I, Neil JF, Perel JM, Rossi AJ, Soloff PH. The pharmacological treatment of delusional depression. Am J Psychiatry 1985;142:430-6.
27. van Moffaert M, de Wilde J, Vereecken A, Dierick M, Evrard JL, Wilmotte J, Mendlewicz J. Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalised patients with major depression. Int Clin Psychopharmacol 1995; 10:3-9.
28. Richou H, Ruimy P, Charbaut J, Delisle JP, Brunner H, Patris M, Zivkov M. A multicentre, double-blind, clomipramine-controlled efficacy and safety study of Org 3770. Hum Psychopharmacol 1995;10:263-71.
29. Zivkov M, de Jongh GD. Org 3770 versus amitriptyline: a 6-week randomized double-blind multicentre trial in hospitalized depressed patients. Hum Psychopharmacol 1995;10:173-80.
30. Clerc GE, Ruimy P, Verdeau-Pailläs J for the Venlafaxine French Inpatient Study Group. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 1994; 9:139-43.
31. Ottevanger EA. The efficacy of fluvoxamine in patients with severe depression. Prog Neuropsychopharmacol Biol Psychiatry 1994;18:731-40.
32. Tignol J, Stroker MJ, Dunbar GC. Paroxetine in the treatment of melancholia and severe depression. Int Clin Psychopharmacol 1992;7:91-4.
33. Pande AC, Sayler ME. Severity of depression and response to fluoxetine. Int Clin Psychopharmacol 1993;8:243-5.
34. Cassano GB, Conti L, Massimetti G, Mengali F, Wakelin JS, Levine J. Use of standardized documentation system in the conduct of a multicenter international trial comparing fluvoxamine, imipramine and placebo. Psychopharmacol Bull 1986;22:52-8.
35. Feighner JP, Boyer WF, Meredith CH, Hendrickson G. A placebo-controlled inpatient comparison of fluvoxamine and imipramine in major depression. Int Clin Psychopharmacol 1989;4:239-44.
36. Kasper S, Möller H-J, Montgomery SA, Zondag E. Antidepressant efficacy in relation to item analysis and severity of depression: a placebo-controlled trial of fluvoxamine versus imipramine. Int Clin Psychopharmacol 1995;9[suppl 4]:3-12.
37. Kasper S, Zivkov M, Roes KCB, Pols AG. Pharmacological treatment of severely depressed patients: a meta-analysis comparing efficacy of mirtazapine and amitriptyline. Eur Neuropsychopharmacol, in press.
38. Fuglum E. Screening and treating depressed patients. A comparison of two controlled citalopram trials across treatment settings: hospitalized patients vs. patients treated by their family doctors. Acta Psychiatr Scand 1996;94:18-25.
39. Montgomery SA, Pedersen V, Tanghøj P, Rasmussen C, Rioux P. The optimal dosing regimen for citalopram - a meta-analysis of nine placebo-controlled studies. Int J Clin Psychopharmacol 1994;9[suppl 1]:35-40.
40. Beasley CM, Holman SL, Potvin JH. Fluoxetine compared with imipramine in the treatment of inpatient depression: a multicenter trial. Ann Clin Psychiatry 1993;5:199-208.
41. Angst J, Amrein R, Stabl M. Moclobemide and tricyclic antidepressants in severe depression: meta-analysis and prospective studies. J Clin Psychopharmacol 1995;15[suppl 2]:16S-23S.
42. Carney MWP, Roth M, Garside RF. The diagnosis of depressive syndromes and the prediction of ECT response. Br J Psychiatry 1965;111:659-74.
43. Stuppaeck CH, Geretsegger C, Whitworth AB, Schubert H, Platz T, König P, Hinterhuber H, Fleischhacker WW. A multicenter double-blind trial of paroxetine versus amitriptyline in depressed inpatients. J Clin Psychopharmacol 1994;14:241-6.
44. Perry PJ. Pharmacotherapy for major depression with melancholic features: relative efficacy of tricyclic versus selective serotonin reuptake inhibitor antidepressants. J Affect Disord 1996; 39:1-6.
45. Nelson JC, Bowers MB Jr. Delusional unipolar depression: description and drug response. Arch Gen Psychiatry 1978;35: 1321-8.
46. Rothschild AJ, Samson JA, Besserte MP, Carter-Campbell JT. Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression. J Clin Psychiatry 1993;54: 338-42.
47. Parker G, Roy K, Hadzi-Pavlovic D, Pedic F. Psychotic (delusional) depression: a meta-analysis of physical treatments. J Affect Disord 1992;16:17-24.
48. Schatzberg AF, Rothschild AJ. Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV? Am J Psychiatry 1992;149:733-15.
49. Gram L. Fluoxetine. N Engl J Med 1995;332:960-1.
50. 2-selective adrenoreceptor antagonist Org 3770 (mirtazapine, Remeron) enhances noradrenergic and serotonergic transmission. Hum Psychopharmacol 1995;10[suppl 2]:S107-19.
51. de Montigny C, Haddjeri N, Mongeau R, Blier P. The effects of mirtazapine on interactions between central noradrenergic and serotonergic systems. CNS Drugs 1995;4:[suppl 1]:13-7.
52. Jacobsen FM. Possible augmentation of antidepressant response by buspirone. J Clin Psychiatry 1991;52:217-20.